Nearly Half of Women Misunderstand Breast Cancer Screening Guidelines
Medically reviewed by Drugs.com
via HealthDay TUESDAY, May 5, 2026 -- Many women are unsure about when to start mammogram screening for breast cancer, according to a survey commissioned by The Ohio State University Comprehensive Cancer Center (OSUCCC) -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The web- and telephone-based survey was conducted from April 2 to 6, 2026, and included 1,043 female respondents.
Results showed widespread confusion about screening guidelines. For example, 44 percent of women incorrectly believe mammograms should start at age 50 years. Roughly half of participants (51 percent) said mammograms should be done every year, and 41 percent believe screening should begin by age 35 years. Among women aged 18 to 29 years, roughly one in four said they would wait until symptoms such as pain or a lump appear before seeing a doctor. Additionally, 53 percent of the women reported a reason for delaying or avoiding mammograms, including: cost (28 percent), discomfort (26 percent), believing they were too young (26 percent), not having symptoms (25 percent), and concerns about radiation exposure (21 percent).
"Our biggest concern is ongoing confusion about screening guidelines," Alyssa Cubbison, D.O., from OSUCCC, said in a statement. "For most women, breast cancer screening should begin with annual mammograms at age 40. Clear, accurate information helps women make informed decisions with their clinician and may lead to earlier detection."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-06 09:30
Read more
- Triple Antihypertensive Pill May Lower Incidence of Recurrent Stroke
- PAS: Balanced Crystalloid Fluid, 0.9 Percent Saline Comparable in Pediatric Septic Shock
- Introduction of HAART Partially Responsible for Resurgence in Syphilis
- Double Shifts Disrupt Normal Cortisol Patterns
- AI Model IDs Pancreatic Ductal Adenocarcinoma at Prediagnostic Stage
- Maternal Prepregnancy BMI, Birth Length Linked to Offspring Atopic Dermatitis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions